View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 3, 2021updated 15 Mar 2022 5:51am

Pfizer commences Phase III trial of RSV vaccine in elderly individuals

The RENOIR trial will analyse the efficacy, immunogenicity and safety of the RSVpreF vaccine candidate in 30,000 subjects.

Pfizer has commenced the Phase III RENOIR clinical trial of a single-dose respiratory syncytial virus (RSV) bivalent prefusion F subunit experimental vaccine candidate, RSVpreF, in adults aged 60 years or above.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

First participants in the trial have been inoculated, the company said.

RSVpreF builds on certain discoveries, including those at the US National Institutes of Health (NIH), which described the crystal structure of a key type of viral protein that RSV leverages to attack human cells.

The international, randomised, double-blind, placebo-controlled Phase III trial will assess the efficacy, immunogenicity and safety of the vaccine in nearly 30,000 subjects.

The safety and efficacy of the vaccine in preventing moderate to severe lower respiratory tract illness (msLRTI-RSV) during the first RSV season will be the trial’s primary goals.

Pfizer Vaccine Research & Development senior vice-president and head Kathrin Jansen said: “There is an important unmet medical need for an effective vaccine that can help protect older adults against this highly contagious disease.

“The start of this Phase III study is an important step forward towards our goal of comprehensive immunisation against RSV disease, which includes developing a potential first vaccine to help prevent RSV disease in adults, as well as the ongoing efforts to help protect infants through maternal immunisation, subject to regulatory approval of the candidate vaccine.”

A common and prevalent cause of acute respiratory illness, RSV is highly contagious and impacts the lungs and airways.

The US Food and Drug Administration granted fast track status to RSVpreF in November 2018 to prevent lower respiratory tract illness caused by RSV in infants by actively immunising pregnant women.

The company reported positive top-line data from Phase IIb proof-of-concept study of the vaccine in April 2020.

This trial assessed the safety, tolerability and immunogenicity of the shot in vaccinated pregnant women aged 18 to 49 years and their infants.

In July 2021, Pfizer offered an update on a Phase IIa trial of RSVpreF in a virus challenge model in healthy adults aged 18 to 50 years.

The data from the Phase IIa trial analysing the safety, immunogenicity and efficacy of the vaccine facilitated the company to progress to Phase III trial.

The latest development comes after Pfizer dosed the first subject in Phase II/III clinical trial of its experimental oral antiviral drug, PF-07321332, for Covid-19 in non-hospitalised patients who have symptoms but are at low risk of progression to severe disease.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena